Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CC-115 · 1 trial · 6 indications
| Arm | Type | Description |
|---|---|---|
| CC-115 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CC-115 | DRUG | Part A (actively recruiting): Dose level starts with 0.5mg daily by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose schedule is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity). Part B: Optimal dose schedule is administered in 28-day cycles until disease progression. |
Inclusion Criteria: * Histologically-confirmed advanced solid tumor, chronic lymphocytic leukemia, small lymphocytic lymphoma, T-cell prolymphocytic leukemia, Non-Hodgkin Lymphoma or multiple myeloma * Progressed or not tolerated standard therapy, and no further standard therapy is available * Arch...
CC-115 is an investigational small molecule being studied for the treatment of glioblastoma multiforme, a type of brain cancer. It is also being evaluated in other advanced solid tumors and hematologic malignancies, including squamous cell carcinoma of the head and neck, prostate cancer, Ewing's osteosarcoma, chronic lymphocytic leukemia, and neoplasm metastasis.
CC-115 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The drug is currently in Phase 1 clinical development for oncology indications.
CC-115 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and tolerability in patients with advanced solid tumors and hematologic malignancies.
CC-115 has been studied in one completed clinical trial, NCT01353625, titled "Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies." The trial enrolled 118 participants across the United States, France, Germany, and Spain.
CC-115 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial, NCT01353625, assessed safety and tolerability, but the drug has not received regulatory approval for any indication.